DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs

A component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users

Evaluation of 17 studies estimates $3.8 million to $10.8 million in annual savings for a 20,000-life population

Aon estimates an additional 1.6 to 2.8 percentage points of potential healthcare cost savings as a result of providing direct access to physicians while simultaneously managing multiple chronic conditions, for potential total of 10% annual savings

Independent analysis finds that evidence supports the economic value of Dario's multi-condition digital health platform for payers including employers, health plans, health systems and accountable care organizations (ACOs)

NEW YORK, Oct. 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the results of a review titled "An Independent Review of Evidence Supporting DarioHealth's Clinical and Cost-Savings Impact" conducted by the Managed Care Services Team of Aon plc ("Aon"), a leading global professional services firm.

Based upon its review of data provided by Dario and published studies identified by Dario, Aon's Managed Care Services Team concluded that the evidence reviewed supports an estimated reduction in total healthcare costs of 2.5% to 7.2% annually across a covered population – measured against total healthcare spend, not only the spend of program participants. For a representative 20,000-life population, that is roughly $3.8 million to $10.8 million a year, depending on disease burden and other factors.

From its analysis of the materials reviewed, Aon concluded that the estimates may be conservative because they exclude two elements of Dario's current service model: management of multiple conditions and providing access to physicians. Aon estimated that these factors may contribute an additional 1.6 to 2.8 percentage points of healthcare cost savings.

The estimate rests on data provided by Dario and Aon's evaluation of 17 studies identified by Dario spanning cardiometabolic, musculoskeletal and behavioral health, including independently conducted research as well as Dario-sponsored studies. Aon observed that the results reported in the reviewed studies were broad and consistent across the identified clinical, behavioral, utilization and cost measures.  The evidence portfolio includes real-world studies using propensity score-matching methodologies together with randomized controlled trials conducted by Dario and third parties. Based on the materials reviewed, Aon concluded the evidence supports an association between Dario's services and meaningful clinical, financial and utilization improvements, and that the observed effects may be generalizable to real-world populations.

"Self-funded employers, health plans and risk-bearing providers, including ACOs, are being asked to cut healthcare costs this year, not in three years" said Erez Raphael, Chief Executive Officer of Dario. "Aon reviewed the data and studies we provided and concluded that the evidence reviewed supports an association between Dario's services and meaningful clinical and financial outcomes in real-world settings.  We believe these findings further demonstrate the value of Dario's approach to chronic condition management."

Important Limitations of Aon's Review

Aon's review was limited to published data, studies, and other materials identified or provided by Dario. Aon did not conduct an independent verification of underlying data, audit the studies, or evaluate all available evidence relating to Dario's services. Aon's conclusions are based solely on the materials reviewed. Outcomes for individual organizations will vary based on their populations, utilization patterns, disease burden and other factors. Aon's conclusions are not a prediction or guarantee of future results and should not be construed as a guarantee of any particular outcome for any specific customer.

About DarioHealth Corp.

DarioHealth (NASDAQ: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses estimations regarding the Company's platform's potential to reduce total healthcare costs, including by up to 10% annually; the Company's expectations regarding the potential healthcare cost savings, clinical, utilization and financial benefits of its platform and services; and the Company's expectations regarding the applicability and generalizability of the results and findings of the studies reviewed by Aon to other populations, customers and real-world settings. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
[email protected]
+1-201-785-6310

Rob Halpern
SVP Marketing
[email protected]

SOURCE DarioHealth Corp.